Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors

NCT02437916 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02437916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02437916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
April 21, 2015
Completion date
December 12, 2016
Enrollment
30 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancy, advanced solid tumors, cancer, colorectal cancer, melanoma, non-small cell lung cancer, oncology, oncology patients, squamous cell carcinoma of the head and neck, transitional cell carinoma of bladder, tumors